Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis

Archives of Internal Medicine

Volumn 172, Issue 10, 2012, Pages 761-769

  Coca, Steven G ^a,c   Ismail Beigi, Faramarz ^d   Haq, Nowreen ^e   Krumholz, Harlan M ^a,b   Parikh, Chirag R ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; CREATININE BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MACROALBUMINURIA; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84861695669     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.2230     Document Type: Review

References (19)

1. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus: the effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications. 1994;8(1):13-17. (Pubitemid 24371436)
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-412. (Pubitemid 30609442)
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
5. Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial investigators. Diabetes Care. 2000;23(10):1478-1485.
6. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2)(suppl 2):S12-S154.
7. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2001; 34:S11-S61. doi:10.2337/dc11-S011.
8. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358 (24):2545-2559.
9. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394-403.
10. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532-2539.
11. Duckworth W, Abraira C, Moritz T, et al VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
12. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl JMed. 2008;358(24):2560-2572. (Pubitemid 351831357)
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
14. Ismail-Beigi F, Craven T, Banerji MA, et al; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376 (9739):419-430.
15. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-B29. (Pubitemid 30185774)
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352 (9131):837-853.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131):854-865.
18. DCCT/EDIC Research Group; de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365(25):2366-2376.
19. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167.